TriSalus Life Sciences (TLSI) Stock Price, News & Analysis

Company Overview

TriSalus Life Sciences, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents. TriSalus collaborates with academic medical centers and cancer research institutions across the United States to advance its candidates through regulatory and clinical milestones. By integrating novel delivery technologies with proven oncology drugs, TriSalus seeks to optimize therapeutic outcomes in both recurrent and metastatic disease settings.

Headquartered in Houston, Texas, TriSalus operates research and development facilities in strategic North American life-science hubs. Its leadership team brings together seasoned professionals with backgrounds in pharmaceutical development, medical devices, and oncology therapeutics. As the company progresses through clinical validation, it plans to expand its technology platform into additional solid tumor indications, aiming to provide safer, more effective treatment options for cancer patients worldwide.

Key Stats

• Today's Range: $3.76 to $4.06
• 50-Day Range: $2.52 to $4.74
• 52-Week Range: $2.20 to $7.95
• Volume: 255,280 shs
• Average Volume: 318,976 shs
• Market Capitalization: $231.55 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.50
• Consensus Rating: Hold

TriSalus Life Sciences Stock Analysis - MarketRank™

TriSalus Life Sciences scored higher than 70% of companies evaluated by MarketBeat, and ranked 180th out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Hold

Consensus Rating

TriSalus Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

TriSalus Life Sciences has a consensus price target of $7.50, representing about 97.9% upside from its current price of $3.79.

Amount of Analyst Coverage

TriSalus Life Sciences has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of TriSalus Life Sciences is -2.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of TriSalus Life Sciences is -2.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.26% of the float of TriSalus Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

TriSalus Life Sciences has a short interest ratio ("days to cover") of 6.76.

Change versus previous month

Short interest in TriSalus Life Sciences has recently increased by 4.15%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TriSalus Life Sciences does not currently pay a dividend.

Dividend Growth

TriSalus Life Sciences does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: N/A

News Sentiment

TriSalus Life Sciences has a news sentiment score of 1.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

MarketBeat Follows

1 people have added TriSalus Life Sciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

4 insiders have purchased shares of TriSalus Life Sciences in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $1,804,176.00 in company stock, which represents 0.7753% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, TriSalus Life Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,804,176.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

16.30% of the stock of TriSalus Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

2.58% of the stock of TriSalus Life Sciences is held by institutions.

Company Calendar

• Last Earnings: 3/05/2026
• Today: 7/08/2026
• Next Earnings (Estimated): 8/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:TLSI
• Previous Symbol: NASDAQ:TLSI
• CIK: 1826667
• Web: trisaluslifesci.com
• Phone: 888-321-5212
• Fax: N/A
• Employees: 106
• Year Founded: 2009

Price Target and Rating

• Average Price Target for TriSalus Life Sciences: $7.50
• High Price Target: $8.00
• Low Price Target: $7.00
• Potential Upside/Downside: +98.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.41)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$39.23 million
• Net Margins: -60.85%
• Pretax Margin: -60.84%
• Return on Equity: N/A
• Return on Assets: -69.91%

Debt

• Debt-to-Equity Ratio: 2.58
• Current Ratio: 5.78
• Quick Ratio: 5.46

Sales & Book Value

• Annual Sales: $45.15 million
• Price / Sales: 5.15
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.68) per share
• Price / Book: -5.57

Miscellaneous

• Outstanding Shares: 61,420,000
• Free Float: 51,406,000
• Market Cap: $232.47 million
• Optionable: Not Optionable
• Beta: 0.43